AbbVie (ABBV) Submits BLA to FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
April 25, 2018 8:45 AM
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that it has submitted a Biologics License Application (BLA) to the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
